|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-5-29
|
|
pubmed:abstractText |
Trastuzumab (Herceptin(R)) improves disease-free survival (DFS) and overall survival for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We aimed to assess the magnitude of its clinical benefit for subpopulations defined by nodal and steroid hormone receptor status using data from the Herceptin Adjuvant (HERA) study.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:BarrDD,
pubmed-author:BaselgaJJ,
pubmed-author:BellRR,
pubmed-author:CameronDD,
pubmed-author:CoatesA SAS,
pubmed-author:ColleoniMM,
pubmed-author:ConstantinCC,
pubmed-author:DeyDD,
pubmed-author:Feng-YiFF,
pubmed-author:GelberR DRD,
pubmed-author:GoldhirschAA,
pubmed-author:HERA Study Team,
pubmed-author:HaslbauerFF,
pubmed-author:JackischCC,
pubmed-author:KhasanovRR,
pubmed-author:Leyland-JonesBB,
pubmed-author:LluchAA,
pubmed-author:MayordomoJ IJI,
pubmed-author:POPRR,
pubmed-author:Piccart-GebhartM JMJ,
pubmed-author:PriceCC,
pubmed-author:ProcterMM,
pubmed-author:Senkus-KonefkaEE,
pubmed-author:SmithII,
pubmed-author:SrimuninnimitVV,
pubmed-author:Suarez SahuiTT,
pubmed-author:UntchMM,
pubmed-author:WermuthPP,
pubmed-author:de AzambujaEE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1090-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18296421-Antibodies, Monoclonal,
pubmed-meshheading:18296421-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18296421-Antineoplastic Agents,
pubmed-meshheading:18296421-Breast Neoplasms,
pubmed-meshheading:18296421-Female,
pubmed-meshheading:18296421-Humans,
pubmed-meshheading:18296421-Internationality,
pubmed-meshheading:18296421-Lymphatic Metastasis,
pubmed-meshheading:18296421-Middle Aged,
pubmed-meshheading:18296421-Receptor, erbB-2,
pubmed-meshheading:18296421-Receptors, Estrogen,
pubmed-meshheading:18296421-Receptors, Progesterone,
pubmed-meshheading:18296421-Survival Analysis
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
|
|
pubmed:affiliation |
Helios Klinikum Berlin Buch, Academic Hospital of the University Charite Berlin, Berlin, Germany.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
